+473.2%
BE vs GSK
+42.7%
+430.5%
-71.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.4% | -1.3% | -0.1% | -1.4% |
| 7D | -18.4% | -3.1% | -15.2% | -18.4% |
| 30D | -24.4% | -0.9% | -23.5% | -24.4% |
| 3M | -18.2% | -4.2% | -14.0% | -18.0% |
| 6M | -33.9% | -1.6% | -32.3% | -34.2% |
| YTD | +96.8% | +2.6% | +94.2% | +92.8% |
| 1Y | +62.9% | +6.2% | +56.7% | +58.3% |
| 3Y | +1,260.2% | +55.0% | +1,205.3% | +1,123.1% |
| 5Y | +473.2% | +42.8% | +430.4% | +333.4% |
| All | +473.2% | +42.7% | +430.5% | +333.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling